BCAB Live signals | Maximize Profits with Getagraph.com

SELL 120133 min ago

@ $2.35

Issued: 14 Feb 2024 @ 09:33

Return: 31.49%

Previous signal: Feb 12 - 10:14

Previous signal: Buy

Return: -12.31 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:00):

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...

Stats
Today's Volume	417 722
Average Volume	608 306
Market Cap	148.65M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.570 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.200
ATR14	$0.00600 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Sievers Eric	Sell	572	Common Stock
2024-04-30	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Sievers Eric	Sell	572	Common Stock
2024-02-29	Smith Scott Andrew	Sell	2 181	Common Stock

INSIDER POWER
93.70
Last 100 transactions
Buy: 3 003 180 \| Sell: 89 297

Volume Correlation

Long: -0.04 (neutral)

Short: 0.26 (neutral)

Signal:(59.169) Neutral

BioAtla, Inc. Correlation

10 Most Positive Correlations
GOSS	0.966
ODT	0.962
SWAV	0.95
TRVN	0.944
XFOR	0.944
THTX	0.941
PAVM	0.935
LYRA	0.933
TCDA	0.931
ENPH	0.931

10 Most Negative Correlations
MLCO	-0.965
ITMR	-0.954
AVEO	-0.95
CCRC	-0.946
TOUR	-0.946
LUNA	-0.941
ACAB	-0.938
TCMD	-0.937
RXDX	-0.937
ALXN	-0.937

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioAtla, Inc. Correlation - Currency/Commodity

0.66
( moderate )

0.48
( neutral )

0.00
( neutral )

-0.73
( moderate negative )

0.00
( neutral )

-0.63
( weak negative )

BioAtla, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2023
Revenue:	$0
Gross Profit:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2022
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-2.70

FY	2021
Revenue:	$250 000
Gross Profit:	$250 000 (100.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Realtime updates for BioAtla, Inc. [BCAB]

Upcoming Earnings Alert